AstraZeneca announces baxdrostat meets the primary endpoint in Bax24 phase III trial in patients with resistant hypertension: Cambridge, UK Wednesday, October 8, 2025, 12:00 Hrs [ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback